Aduro Biotech Inc. announced that its pancreatic cancer drug did not improve overall survival in patients who did not show improvement after at least two prior therapies, reports Reuters.
The announcement comes following a mid-stage study of Aduro's Phase 2b ECLIPSE trial.
According to Robin Evans of The Point Review, Aduro management reviewed the results in more detail during a conference call Monday, May 16. Full study findings will be presented at a future scientific congress.
“This is an unexpected outcome, and we are disappointed particularly for the pancreatic cancer patients who are in need of additional treatment options,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro.
Review the full report from The Point Review here, in which Evans details the company’s stock standings, financial station and more.